You have full text access to this OnlineOpen article

Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphoma

  1. Nam H. Dang1,
  2. Luis Fayad2,
  3. Peter McLaughlin2,
  4. Jorge E. Romaguara2,
  5. Fredrick Hagemeister2,
  6. Andre Goy2,
  7. Sattva Neelapu2,
  8. Felipe Samaniego2,
  9. Pamela L. Walker2,
  10. Michael Wang2,
  11. Maria A. Rodriguez2,
  12. Ann T. Tong3,
  13. Barbara Pro2

Article first published online: 29 JUN 2007

DOI: 10.1111/j.1365-2141.2007.06684.x

Issue

British Journal of Haematology

British Journal of Haematology

Volume 138, Issue 4, pages 502–505, August 2007

Additional Information

How to Cite

Dang, N. H., Fayad, L., McLaughlin, P., Romaguara, J. E., Hagemeister, F., Goy, A., Neelapu, S., Samaniego, F., Walker, P. L., Wang, M., Rodriguez, M. A., Tong, A. T. and Pro, B. (2007), Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphoma. British Journal of Haematology, 138: 502–505. doi: 10.1111/j.1365-2141.2007.06684.x

Author Information

  1. 1

    Department of Hematologic Malignancies, Nevada Cancer Institute, Las Vegas, NV

  2. 2

    Department of Lymphoma/Myeloma

  3. 3

    Department of Cardiology, MD Anderson Cancer Center, Houston, TX, USA

*Nam H. Dang, Department of Hematologic Malignancies, Nevada Cancer Institute, 10441 W. Twain Avenue, Las Vegas, NV 89135, USA. E-mail: ndang@nvcancer.org

Publication History

  1. Issue published online: 29 JUN 2007
  2. Article first published online: 29 JUN 2007
  3. Received 20 April 2007; accepted for publication 15 May 2007

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (447K)

Keywords:

  • denileukin difitox;
  • non-Hodgkin lymphoma;
  • follicular lymphoma;
  • rituximab

Summary

Denileukin diftitox plus rituximab was evaluated in relapsed/refractory B-cell non-Hodgkin lymphoma patients. Of the 38 evaluable patients, 30 (80%) were rituximab-refractory. The overall response rate (ORR) was 32%, with six complete responses (CR) and six partial responses (PR). The median time to progression for responders was 8 months (range: 2–36+); two patients with rituximab-refractory follicular lymphoma were in CR at 25 and 36+ months. The ORR was 55% (4 CRs, 2 PRs) in 11/14 patients with rituximab-refractory follicular lymphoma, and 100% in the three patients with rituximab-sensitive tumour. Most toxicities were low grade and transient, and myelotoxicity was uncommon.

View Full Article (HTML) Get PDF (447K)